What stands out about Select Medical Holdings right now
Select Medical Holdings (SEM) has drawn investor attention recently, with the share price around $16.25 and mixed return patterns over the past year, raising questions about how its current valuation lines up with fundamentals.
See our latest analysis for Select Medical Holdings.
Recent trading has been firm, with a 7 day share price return of 8.6% and a 90 day share price return of 9.0%. However, the 1 year total shareholder return of a 7.6% decline and 5 year total shareholder return of a 5.0% decline suggest improving short term momentum set against weaker longer term results.
If this move in a healthcare operator has you thinking about where else capital could work, it might be a good time to look at 32 healthcare AI stocks as potential next ideas.
With the share price close to the US$16.63 analyst target and an intrinsic value estimate sitting slightly higher, the key question is whether SEM is quietly undervalued or if the market is already pricing in its future growth.
Most Popular Narrative: 8.9% Undervalued
Compared with the last close at $16.25, the most widely followed narrative points to a fair value of about $18.33, using a discount rate of 8.33% and detailed long term assumptions on revenue, margins and capital intensity.
Policy and payer shifts toward value-based and cost-effective care settings favor Select Medical's post-acute and rehab offerings. This may boost occupancy rates and reduce earnings volatility as payers and hospitals increasingly steer patients to these lower-cost, high-quality care environments.
Read the complete narrative. Read the complete narrative.
Curious what kind of revenue trajectory, margin uplift and earnings multiple are needed to reach that fair value? The narrative spells out the full math behind those expectations.
Result: Fair Value of $18.33 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh the pressure from regulatory reimbursement changes and the company’s US$1.9b debt load, which could constrain earnings and flexibility.
Find out about the key risks to this Select Medical Holdings narrative.
Another View: Cash Flows Paint a Harsher Picture
There is a catch. While the narrative-based fair value sits near $18.33 and points to SEM looking mildly undervalued, our DCF model points the other way, with an estimate of future cash flow value closer to $5.73 per share. On that framework, the shares screen as overvalued.
The gap between a cash flow driven value near $5.73 and a market price of $16.25 raises a practical question for you as an investor: which story about SEM’s future cash generation do you trust more, and what would need to change before those two views meet in the middle?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Select Medical Holdings for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of opportunity and concern feels finely balanced, it may be worth taking a closer look now and forming your own view with 3 key rewards and 3 important warning signs.
Ready to hunt for your next idea?
If SEM has sharpened your focus, do not stop here. Broaden your watchlist now so you are not looking back at missed chances later.
- Target potential value by checking companies that screen as underpriced relative to fundamentals through our 50 high quality undervalued stocks and see what stands out to you.
- Strengthen your income backbone by reviewing dependable payers in our 16 dividend fortresses and spot yields that fit your approach.
- Protect your downside first by filtering for resilient names using our 63 resilient stocks with low risk scores before you commit fresh capital.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com